trending Market Intelligence /marketintelligence/en/news-insights/trending/nHgSD4pILD8rPvTbb0A1cg2 content esgSubNav
In This List

Oragenics plans common stock offering to fund research, clinical trials

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Oragenics plans common stock offering to fund research, clinical trials

Oragenics Inc. started an underwritten public offering of common shares and warrants to buy common shares.

The underwriter will have an option to buy additional common shares and warrants at the public offering price.

Tampa, Fla.-based Oragenics plans to use net proceeds to fund research of its drug candidate AG013, a potential treatment for oral mucositis in cancer patients. Oral mucositis, or mouth sores, are a common complication of cancer treatments.

Proceeds will also be used for clinical trials and preclinical development of the company's lantibiotics program, and for working capital and general corporate purposes.

H.C. Wainwright & Co. is the sole book-running manager for the offering.